LONG BEACH, Calif. -- Depletion of a payment assistance program has translated into worse vision outcomes for older patients ...

The Regeneron litigation highlights that donations routed through independent entities are not immune from challenge, especially if the government believes they are effectively covering a patient’s co ...

From tariffs to drug pricing to the FDA, biopharma CEOs find themselves pulled into policy discussions on this year’s second quarter earnings calls.

In patients with diabetic macular edema in both eyes, the port delivery system in one eye achieves a superior anatomical ...

Genetic testing company Natera (NASDAQ:NTRA). will be announcing earnings results this Thursday after market hours. Here’s ...

Trump is pushing drug companies to lower their prices, but experts cast doubt on how effective this endeavor will prove.

Detailed price information for Regeneron Pharmaceuticals (REGN-Q) from The Globe and Mail including charting and trades.

Second quarter earnings season is in full swing, and the results have been largely positive so far, with more positive ...

The market for chronic obstructive pulmonary disease treatment devices is projected to witness substantial growth, fueled by ...

Detailed price information for Regeneron Pharmaceuticals (REGN-Q) from The Globe and Mail including charting and trades.

About Splunk LLC Splunk, a Cisco company, helps build a safer and more resilient digital world. Organizations trust Splunk to ...

The administration wants drugmakers to bring medication prices more closely in line with the Most-Favored Nation pricing approach.